A Comparison of the Clinical Impact of Bleeding Measured by Two Different Classifications Among Patients With Acute Coronary Syndromes  by Rao, Sunil V. et al.
A
B
A
S
L
D
F
D
a
C
h
u
c
p
b
f
e
t
e
c
(
O
T
i
c
o
§
h
R
2
Journal of the American College of Cardiology Vol. 47, No. 4, 2006
© 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00
PComparison of the Clinical Impact of
leeding Measured by Two Different Classifications
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unil V. Rao, MD,* Kristi O’Grady, MS,* Karen S. Pieper, MS,* Christopher B. Granger, MD, FACC,*
. Kristin Newby, MD, MHS, FACC,* Kenneth W. Mahaffey, MD, FACC,*
avid J. Moliterno, MD, FACC,† A. Michael Lincoff, MD, FACC,‡ Paul W. Armstrong, MD, FACC,§
rans Van de Werf, MD, FACC, Robert M. Califf, MD, FACC,* Robert A. Harrington, MD, FACC*
urham, North Carolina; Lexington, Kentucky; Cleveland, Ohio; Edmonton, Alberta, Canada;
nd Leuven, Belgium
OBJECTIVES The goal of this study was to determine the association between Thrombolysis In Myocardial
Infarction (TIMI) and Global Use of Strategies to Open Occluded Coronary Arteries
(GUSTO) bleeding and clinical outcomes.
BACKGROUND There are limited data on the relative utility of either scale at predicting clinical outcomes in
patients with non–ST-segment elevation acute coronary syndromes (ACS).
METHODS Pooled data from two randomized trials of patients with ACS (n  15,454) were analyzed to
determine the association between TIMI and GUSTO bleeding and 30-day and 6-month
death/myocardial infarction (MI) using Cox proportional hazards modeling that included
bleeding as a time-dependent covariate.
RESULTS There was a stepwise increase in the adjusted hazard of 30-day death/MI with worsening
GUSTO bleeding (hazard ratio [95% confidence interval], GUSTO mild 1.20 [1.05 to 1.37];
moderate 3.28 [2.88 to 3.73]; severe 5.57 [4.33 to 7.17]), and an increased risk with all three
levels of TIMI bleeding (TIMI minimal 1.84 [1.63 to 2.08]; TIMI minor 1.64 [1.31 to 2.04];
major 1.45 [1.23 to 1.70]). When both bleeding scales were included in the same model, the
risk with GUSTO bleeding persisted; however, the association between TIMI bleeding and
outcome was no longer significant.
CONCLUSIONS Both scales identify ACS patients with bleeding complications at risk for adverse outcomes.
In a model that included both definitions, the risk with GUSTO bleeding persisted while the
risk with TIMI bleeding did not. This suggests that bleeding assessed with clinical criteria is
more important than that assessed by laboratory criteria in terms of outcomes. Future clinical
trials should consider using a combination of the GUSTO bleeding scale and the need for
transfusion to assess bleeding complications. (J Am Coll Cardiol 2006;47:809–16) © 2006
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.09.060by the American College of Cardiology Foundation
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dontemporary therapy for the treatment of acute ischemic
eart disease includes anti-thrombotic medications and the
se of early invasive risk stratification (1). While this
ombination of treatments has improved the outcomes of
atients with acute coronary syndromes (ACS), the risk of
leeding remains a significant issue (2,3). Cognizant of this
act, clinical investigators systematically identify bleeding
vents that occur during the course of randomized clinical
rials. Although guidelines exist for classifying bleeding
vents (4), many clinical trials utilize one of two bleeding
lassifications: the Thrombolysis In Myocardial Infarction
TIMI) classification, and/or the Global Use of Strategies to
pen Occluded Coronary Arteries (GUSTO) classification.
he existence of these two systems often leads to disparities
n the reported incidence of bleeding events within the same
linical trial. For example, in the Platelet Glycoprotein
From the *Duke Clinical Research Institute, Durham, North Carolina; †University
f Kentucky, Lexington, Kentucky; ‡Cleveland Clinic Foundation, Cleveland, Ohio;
University of Alberta, Edmonton, Alberta, Canada; and the Universitaire Zieken-
uizen Leuven, Leuven, Belgium. This analysis was supported by the Duke Clinical
esearch Institute, Durham, North Carolina.B
Manuscript received February 17, 2005; revised manuscript received August 26,
005, accepted September 9, 2005.Ib/IIIa in Unstable Angina: Receptor Suppression Using
ntegrilin Therapy (PURSUIT) trial, the rate of TIMI
ajor bleeding among patients assigned to the platelet
nhibitor eptifibatide was 3.0%, yet the rate of GUSTO
evere bleeding in this same group was 1.1%. Moreover, the
roportion of patients receiving eptifibatide deemed to have no
IMI bleeding was 84.2%, but the proportion deemed to have
oGUSTO bleeding was 68.8%. There are limited data on the
elative merits of either scale at predicting clinical outcomes.
e analyzed data from two large multicenter randomized
linical trials to compare the association between the different
egrees of in-hospital TIMI and GUSTO bleeding and short-
nd intermediate-term clinical outcomes.
ETHODS
atient population and treatments. Clinical data from the
ulticenter international PURSUIT trial (n  10,798) and
he Platelet IIb/IIIa Antagonism for the Reduction of Acute
oronary Syndrome Events in a Global Organization Net-
ork (PARAGON) B trial (n  5,225) were pooled. The
etails of the trials have been published elsewhere (5,6).
riefly, patients with acute non–ST-segment elevation ACS
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Bleeding by Two Different Scales and Outcomes February 21, 2006:809–16nrolled in the PURSUIT trial were randomly assigned to
eceive the intravenous glycoprotein IIb/IIIa inhibitor epti-
batide or placebo. Patients with non–ST-segment eleva-
ion ACS enrolled in the PARAGON B trial were ran-
omly assigned to receive the intravenous glycoprotein
Ib/IIIa inhibitor lamifiban or placebo. For the current
tudy, the analysis was limited to the patients from the two
rials that had complete data on end points.
Concomitant treatment with aspirin (dose ranges be-
ween 80 and 325 mg daily) and antithrombin agents was
ecommended by protocol in both trials. The use of other
edications and procedures was at the discretion of the
reating physicians.
efinitions and end points. BLEEDING. The TIMI bleeding
lassification is a laboratory-based scale (7) while the
USTO bleeding classification is a clinically based scale (8)
Table 1). The TIMI definition of bleeding uses four
ategories: major, minor, minimal, and none. The GUSTO
leeding definition also uses four categories: severe or
ife-threatening, moderate, mild, and none. The PURSUIT
nvestigators used both definitions to classify bleeding
vents. The PARAGON investigators defined bleeding
omplications as major or life-threatening, and intermedi-
te. Major or life-threatening bleeding was defined as any
ntracranial hemorrhage or bleeding leading to hemodynamic
ompromise requiring intervention. Intermediate bleeding was
efined as bleeding requiring transfusion or a decrease in
emoglobin 5 g/dl or more (or decrease in hematocrit 15%
hen hemoglobin was unavailable). For the purpose of this
nalysis, the TIMI and GUSTO classifications were recon-
tructed from the detailed clinical data (Appendix).
Data on the date, time, severity, and location (including
unidentifiable”) of each in-hospital bleeding event were
ollected prospectively. Detailed clinical data, including
reatments (such as blood transfusion), baseline, and nadir
emoglobin or hematocrit values after each bleeding event,
nd hemodynamic status during each bleeding event, were
ollected on all patients in both trials. For patients who
xperienced more than one bleeding episode, only the most
Abbreviations and Acronyms
ACS  acute coronary syndrome
CABG  coronary artery bypass grafting
GUSTO  Global Use of Strategies to Open
Occluded Coronary Arteries
MI  myocardial infarction
PARAGON  Platelet IIb/IIIa Antagonism for the
Reduction of Acute Coronary Syndrome
Events in a Global Organization
Network trial
PURSUIT  Platelet Glycoprotein IIb/IIIa in
Unstable Angina: Receptor Suppression
Using Integrilin Therapy trial
TIMI  Thrombolysis In Myocardial Infarctionevere bleeding episode was considered. TND POINTS. The primary end point of our study was the
ccurrence of death or recurrent myocardial infarction (MI)
t 30 days. The secondary end point was the occurrence of
eath or recurrent MI at six months. Myocardial infarction
as defined according to the protocol of each trial (5,6). All
eath and MI events for each trial were adjudicated by an
ndependent blinded events committee.
tatistical analysis. Patients were grouped according to the
resence or absence of a bleeding event. Patients who
xperienced a bleeding event were further classified based on
leeding severity according to the TIMI and GUSTO
cales. Categorical variables are expressed as percentages,
nd continuous variables are expressed as medians and
nterquartile ranges. Baseline characteristics were compared
sing chi-square tests for categorical variables and the
on-parametric Kruskal-Wallis test for continuous vari-
bles. Baseline differences with p values 0.01 were con-
idered significant.
We compared unadjusted rates of the primary and sec-
ndary end points among patients with no bleeding and
hose within the various categories of TIMI and GUSTO
leed severity. To determine the association between bleed-
ng severity as defined by the two scales and the primary and
econdary outcomes, we constructed separate models for
ach bleeding definition. Because bleeding is a post-
andomization event that can change over time, and can
nfluence and be influenced by treatments (e.g., procedures)
able 1. Key Elements of the TIMI and GUSTO
leeding Classifications
TIMI Bleeding Classification (7)*
ajor Intracranial hemorrhage or a 5 g/dl decrease in the
hemoglobin concentration or a 15% absolute
decrease in the hematocrit
inor Observed blood loss: 3 g/dl decrease in the
hemoglobin concentration or 10% decrease in
the hematocrit
No observed blood loss: 4 g/dl decrease in the
hemoglobin concentration or 12% decrease in
the hematocrit
inimal Any clinically overt sign of hemorrhage (including
imaging) that is associated with a 3 g/dl
decrease in the hemoglobin concentration or 9%
decrease in the hematocrit
GUSTO Bleeding Classification (8)
evere or
life-threatening
Either intracranial hemorrhage or bleeding that
causes hemodynamic compromise and
requires intervention
oderate Bleeding that requires blood transfusion but
does not result in hemodynamic compromise
ild Bleeding that does not meet criteria for either
severe or moderate bleeding
All TIMI definitions take into account blood transfusions, so that hemoglobin and
ematocrit values are adjusted by 1 g/dl or 3%, respectively, for each unit of blood
ransfused. Therefore, the true change in hemoglobin or hematocrit if there has been
n intervening transfusion between two blood measurements is calculated as follows:
Hemoglobin  [baseline Hgb  post-transfusion Hgb]  [number of transfused
nits];  Hematocrit  [baseline Hct  post-transfusion Hct]  [number of
ransfused units  3].
GUSTO  Global Strategies for Opening Occluded Coronary Arteries; TIMI 
hrombolysis In Myocardial Infarction.
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February 21, 2006:809–16 Bleeding by Two Different Scales and Outcomesnd adverse events (e.g., MI), both models incorporated
leeding as a time-dependent covariate in a Cox regression.
his technique minimizes confounding by considering only
hose bleeding events that transpired before the occurrence
f the end points (9). Variables entered into both models
ere based on a comprehensive set of baseline variables
rom a validated model of outcome among patients with
on–ST-segment elevation ACS (10) (c-index  0.81) and
ncluded patient characteristics, presenting signs and symp-
oms, and treatments, including blood transfusion.
The first model incorporated TIMI bleed severity as a
ime-dependent covariate and used “no TIMI bleeding”
s the reference. The second model incorporated GUSTO
leed severity as a time-dependent covariate and used “no
USTO bleeding” as the reference. Due to the potential
nfluence of blood transfusion on outcomes (11), we
epeated the analysis after adjusting for transfusion by
reating a dichotomous time-dependent variable that
oded transfusion of at least 1 U of blood. We also
epeated the analysis by constructing a model that in-
luded both bleeding scales as time-dependent covariates.
dditional models were generated to evaluate the effect
f each bleed scale in the presence or absence of the other
cale. The models were adjusted for baseline covariates
nd included the scale of interest (e.g., the GUSTO
cale) plus an indicator for any bleed according to the
ther scale (e.g., any type of TIMI bleed) versus no bleed
ccording to the other scale (e.g., no TIMI bleed of any sort).
nother set of models included the interaction of these two
ariables. Because coronary artery bypass surgery (CABG) can
nfluence the severity of bleeding as well as outcomes, we
epeated the analysis again for the entire patient cohort with
ensoring at the time of CABG. Finally, we used interaction
erms to explore the effect of patient age, gender, weight, and
enal function on TIMI and GUSTO bleeding levels in
redicting short- and intermediate-term death or MI. All
nalyses were performed using SAS Version 8.2 (SAS Insti-
ute, Cary, North Carolina).
thics of protocol. The institutional review boards of all
articipating institutions reviewed and approved the proto-
ols of the PURSUIT and PARAGON B trials. All
nrolled patients gave written informed consent.
ESULTS
iming of events and baseline characteristics. A total of
5,454 patients from the two trials had complete data on
nd points. Among patients with a bleeding event, the
edian time from randomization to the most severe TIMI
leeding event was 1.0 days (25th, 75th percentile: 1.0, 2.0).
he median time to the most severe GUSTO bleeding
vent was 2.0 days (1.0, 6.0). The median times to PCI and
ABG procedures were 3.8 days (1.2, 9.8) and 9.9 days
4.1, 30.3), respectively. There were 1,151 patients who met
riteria for GUSTO bleeding that did not meet criteria for
IMI bleeding, and 765 patients who met criteria for TIMI tleeding that did not meet criteria for GUSTO bleeding.
here were 3,758 patients who met criteria for both TIMI
nd GUSTO bleeding.
With regard to TIMI bleeding, 12.7% of patients expe-
ienced a TIMI minimal bleed, 8.5% of patients experienced
TIMI minor bleed, and 8.2% experienced a TIMI major
leed. Table 1 shows the baseline characteristics of the
atients who developed TIMI bleeding by the severity of
he bleeding event. There were significant differences in
aseline characteristics across the TIMI bleeding categories
o that patients with a TIMI minor bleed were older, more
ften of non-white race and female, more often had cardiac
isk factors, and were sicker at presentation compared with
hose having either a TIMI minimal or major bleed. In
ddition, a higher proportion of patients with TIMI minor
leeding had undergone in-hospital PCI compared with
hose with TIMI minimal or major bleeding. In contrast, a
igher proportion of patients who experienced a TIMI
ajor bleed had prior hyperlipidemia, prior MI, prior
ongestive heart failure, and prior stroke. A higher propor-
ion of patients with TIMI minimal bleeding had under-
one cardiac catheterization and CABG compared with
hose who experienced TIMI minor or major bleeding.
pproximately one-third of the patients with TIMI mini-
al, minor, and major bleeding underwent blood transfu-
ion during the hospitalization. Significantly more patients
ith TIMI bleeding who underwent CABG were trans-
used compared with patients with TIMI bleeding who did
ot undergo CABG (18% vs. 4.6%, p  0.001).
The proportion of patients with GUSTO mild, moder-
te, and severe bleeding was 19.2%, 11.4%, and 1.2%, respec-
ively. Table 2 shows the baseline characteristics of patients
y worsening GUSTO bleed severity. As the GUSTO
leeding severity worsened, there was a gradient of increas-
ng age, increasing proportion of patients of non-white race,
nd an increasing proportion of patients with hypertension,
iabetes mellitus, prior MI, prior stroke, prior PCI, chronic
enal insufficiency, and patients presenting with higher
illip class and higher heart rate. Patients who experienced
GUSTO moderate bleed had undergone cardiac catheter-
zation and/or CABG during hospitalization more often
han those experiencing mild or severe bleed, while patients
ho experienced a GUSTO mild bleed had undergone PCI
ore often than those who experienced a moderate or severe
leed. Very few patients with GUSTO mild bleeding
nderwent blood transfusion while a large proportion of
atients with GUSTO moderate and severe bleeding re-
eived blood transfusion. Significantly more patients with
USTO bleeding who underwent CABG received trans-
usion compared with patients with GUSTO who did not
ndergo CABG (53.5% vs. 10.0%, p  0.001).
utcomes. Tables 2 and 3 show the unadjusted rates of
0-day and 6-month death or MI for patients who experi-
nced various levels of TIMI and GUSTO bleeding. After
ultivariable adjustment, there was a stepwise increase inhe adjusted hazard of the primary and secondary end points
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Bleeding by Two Different Scales and Outcomes February 21, 2006:809–16s GUSTO bleeding severity worsened (Figs. 1A and 1B).
here was also an increased adjusted risk with each level of
IMI bleeding, but the point estimates of the hazard ratios
or each level of TIMI bleeding were similar to each other.
fter adjustment for blood transfusion, the stepwise in-
rease in the risk of short- and intermediate-term outcomes
ith worsening GUSTO bleeding persisted; however, the
ssociation between TIMI bleeding severity and six-month
dverse outcomes was no longer statistically significant
Figs. 2A and 2B). When both bleeding scales were in-
luded in the same model, the stepwise increase in the risk
or 30-day and 6-month death or MI with worsening
USTO bleeding was evident, but there was no significant
ncrease in risk with any level of TIMI bleeding (Figs. 3A
nd 3B). The analysis was repeated with censoring at the
ime of CABG, and the results were nearly identical (data
ot shown). There were no significant interactions between
atient age, gender, weight, or renal function and TIMI
leeding. There was a significant interaction between age and
USTO moderate bleeding such that the increased risk of
eath or MI with GUSTO moderate bleeding was more
ronounced among younger patients. There was a significant
nteraction between GUSTO and TIMI bleeding (p 
able 2. Baseline Characteristics of Patients by TIMI Bleeding S
Characteristics
No Bleeding
(n  10,925)
emographic
Median age, yrs (25th, 75th percentiles) 63.0 (54.0, 71.0) 6
Female patients 34.7
Non-white race 11.5
Median weight, kg (25th, 75th percentiles) 78.0 (68.9, 88.0) 7
edical history
Diabetes mellitus 21.8
Hypertension 55.0
Hyperlipidemia 44.3
Chronic renal insufficiency 0.6
Prior MI 31.4
Prior stroke 5.5
Prior PCI 13.7
Prior CABG 12.3
Prior CHF 10.5
resenting signs
Median systolic blood pressure, mm Hg
(25th, 75th percentiles)
131.0 (120.0, 150.0) 13
Killip class 2 1.4
n-hospital procedures
Cardiac catheterization* 49.7
PCI* 20.3
CABG* 6.4
lood transfusion
During hospitalization 2.2
Within 24 h after bleed N/A
utcomes
30-day death or MI 10.8
6-month death or MI 14.4
Within 7 days of randomization.
CABG  coronary artery bypass grafting; CHF  congestive heart failure; GU
nfarction; PCI  percutaneous coronary intervention; TIMI  Thrombolysis In M.0001). The risk for the 30-day and 6-month end points for lUSTO bleeding without TIMI bleeding was higher than the
isk withGUSTO bleeding with any degree of TIMI bleeding.
ISCUSSION
ur study has several important findings. First, we have
hown that both the GUSTO and TIMI bleeding scales
dentify patients at increased risk for adverse clinical events.
his risk was manifest primarily within 30 days after the
leeding event. Second, we found that each scale identifies
atients with bleeding events that are missed by the other
cale. Third, after adjustment for blood transfusion, the
tepwise increase in risk with worsening GUSTO bleeding
ersisted while the risk with TIMI bleeding was no longer
tatistically significant. Finally, when both bleeding defini-
ions were included in the same model only GUSTO
leeding was associated with a worse prognosis. When
xploring interaction terms between the two bleeding scales,
e found that TIMI bleeding did not affect the risk among
atients who also met criteria for GUSTO bleeding. This
uggests that in terms of adverse outcomes, assessment of
leeding using clinical criteria is more important than using
ty (Numbers Shown Are Percentages Unless Otherwise Noted)
I Minimal
leeding
 1,955)
TIMI Minor
Bleeding
(n  1,308)
TIMI Major
Bleeding
(n  1,266)
p Value
for Trend
57.0, 72.0) 68.0 (59.0, 74.0) 65.0 (56.0, 72.0) 0.001
37.9 39.8 33.9 0.001
11.1 14.4 5.0 0.001
68.5, 88.0) 77.0 (67.0, 87.0) 77.0 (68.0, 86.4) 0.021
22.8 28.4 23.8 0.001
58.2 61.2 56.1 0.001
45.7 43.8 47.1 0.144
0.4 2.0 0.9 0.001
32.8 31.4 34.1 0.140
6.2 7.8 8.0 0.001
15.6 13.5 8.9 0.001
11.3 12.9 8.5 0.001
10.0 13.5 15.0 0.001
116.0, 145.0) 130.0 (119.0, 150.0) 138.0 (120.0, 153.0) 0.001
1.2 2.6 1.8 0.001
69.8 60.7 43.5 0.001
24.5 28.2 11.8 0.001
23.8 16.6 20.0 0.001
32.2 28.6 31.6 0.001
5.0 7.7 18.0 0.001
19.9 22.0 21.5 0.001
22.4 26.7 24.9 0.001
 Global Strategies for Opening Occluded Coronary Arteries; MI  myocardial
ial Infarction.everi
TIM
B
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February 21, 2006:809–16 Bleeding by Two Different Scales and OutcomesOur study has important implications for both clinical
are and clinical research. Both bleeding definitions were
eveloped to classify bleeding complications of thrombolytic
herapy (7,8), and have not been previously validated in the
etting of non–ST-segment elevation ACS. Other investi-
ators have explored the incidence and predictors of bleed-
ng complications in this population (2,12,13), but the bleed-
ng definitions used varied across studies, and outcomes
ere not specifically examined. Our results add to these
revious studies by demonstrating that that bleeding com-
lications, regardless of severity, are associated with worse
linical outcomes among patients with acute ischemic heart
isease in whom thrombolytic therapy is not used. While
his increased risk persisted for all levels of GUSTO bleeding
ven after adjusting for blood transfusion, it did not persist for
IMI bleeding after accounting for transfusion. Because one
ifference between the TIMI and GUSTO scales is whether
ransfusion is necessary, our results suggest that patients who
xperience TIMI bleeding who do not require transfusion
i.e., asymptomatic decreases in hemoglobin) are not at risk
or adverse outcomes. Therefore, liberal use of blood trans-
usion in these patients may expose them to the risks of
ransfusion (11,14) without any clear benefit. These data
able 3. Baseline Characteristics of Patients by GUSTO Bleeding S
Characteristics
No Bleeding
(n  10,546)
emographic
Median age, yrs (25th, 75th percentiles) 63.0 (53.0, 70.0) 6
Female patients 33.4
Non-white race 11.2
Median weight, kg (25th, 75th percentiles) 78.0 (69.0, 88.0) 7
edical history
Diabetes mellitus 21.5
Hypertension 54.0
Hyperlipidemia 43.4
Chronic renal insufficiency 0.5
Prior MI 30.8
Prior stroke 5.3
Prior PCI 12.4
Prior CABG 11.8
Prior CHF 10.8
resenting signs
Median systolic blood pressure, mm Hg
(25th, 75th percentiles)
131.0 (120.0, 150.0) 13
Killip class 2 1.4
n-hospital procedures
Cardiac catheterization* 43.8
PCI* 18.6
CABG* 2.3
lood transfusion
During hospitalization 0.2
Within 24 h after bleed N/A
utcomes
30-day death or MI 10.7
6-month death or MI 14.1
Within 7 days of randomization.
CABG  coronary artery bypass grafting; CHF  congestive heart failure; GU
nfarction; PCI  percutaneous coronary intervention; TIMI  Thrombolysis In Mlso provide support for clinical practice guidelines that biscourage the use of blood transfusions in patients who are
linically stable regardless of their nadir hemoglobin or
ematocrit value (15).
Although our study is the first to provide evidence for the
ssociation between bleeding as measured by both the
USTO and TIMI bleeding classifications and clinical
utcomes in the setting of non–ST-segment elevation ACS,
hese definitions have been used either alone or in combi-
ation in cardiovascular clinical trials over the last two
ecades (5,16–24). This has resulted in wide variation in the
ates of bleeding complications that have been reported with
arious antithrombotic agents. For example, in the Superior
ield of the New Strategy of Enoxaparin, Revascularization
nd Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial of
noxaparin versus unfractionated heparin, the rate of TIMI
ajor bleeding was 9.7% among patients assigned to enox-
parin, but the rate of GUSTO severe bleeding was only
.7% (24). In the context of this disparity, our study
uggests that the guidelines for measuring bleeding among
atients with ACS (4) should be amended to include a more
ptimal metric—a combination of the clinically-based
USTO scale and need for blood transfusion. Bleeding
omplications with limited prognostic value as determined
ty (Numbers Shown Are Percentages Unless Otherwise Noted)
TO Mild
leeding
 2,965)
GUSTO Moderate
Bleeding
(n  1,756)
GUSTO Severe
Bleeding
(n  187)
p Value
for Trend
56.0, 73.0) 67.0 (60.0, 73.0) 68.0 (60.0, 74.0) 0.001
38.2 38.9 38.0 0.001
10.5 11.7 18.3 0.001
68.2, 88.5) 75.0 (66.0, 86.0) 78.4 (67.0, 90.0) 0.001
23.0 26.7 34.2 0.001
58.6 59.8 62.0 0.001
46.1 48.5 43.2 0.001
0.7 1.9 2.7 0.001
32.6 34.1 35.8 0.013
6.6 7.9 12.3 0.001
14.9 15.8 17.8 0.001
13.3 10.4 16.0 0.006
12.2 11.2 15.5 0.038
120.0, 150.0) 132.0 (120.0, 150.0) 130.5 (120.0, 148.0) 0.400
1.9 2.0 2.2 0.001
60.6 69.4 61.0 0.001
31.3 11.5 18.7 0.001
7.5 43.3 30.5 0.001
0.8 82.4 83.4 0.001
0.3 69.4 70.4 0.001
13.5 29.3 49.7 0.001
17.4 32.0 59.5 0.001
 Global Strategies for Opening Occluded Coronary Arteries; MI  myocardial
ial Infarction.everi
GUS
B
(n
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3.0 (y the laboratory-based TIMI scale may continue to have a
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Bleeding by Two Different Scales and Outcomes February 21, 2006:809–16ole in guiding dosing decisions for new anticoagulants that
re in development.
tudy limitations. Our study has some limitations. First,
ur study was not designed to evaluate the definitions of
leeding per se. Rather, we sought to delineate the associ-
tion between bleeding defined by two of the most com-
only used bleeding scales and clinical outcomes. Second,
ur results could be the result of ascertainment bias. The
dentification of TIMI bleeding events could be limited if
igure 1. (A) Adjusted hazard ratios of 30-day death or myocardial
nfarction (MI) by worsening Global Strategies for Opening Occluded
oronary Arteries (GUSTO) and Thrombolysis In Myocardial Infarction
TIMI) bleeding severity. Separate models constructed for each bleeding
cale. Adjusted for age, gender, weight, site, diabetes mellitus, smoking
tatus, prior angina, peripheral vascular disease, pre-randomization ther-
py, MI at enrollment, systolic blood pressure at randomization, diastolic
lood pressure at randomization, heart rate at randomization, Killip class,
nd assigned treatment. (B) Adjusted hazard ratios for six-month death or
I by worsening GUSTO and TIMI bleeding severity. Separate models
onstructed for each bleeding definition. Separate models constructed for
ach scale. Adjusted for age, gender, weight, site, diabetes mellitus,
moking status, prior angina, peripheral vascular disease, pre-
andomization therapy, MI at enrollment, systolic blood pressure at
andomization, diastolic blood pressure at randomization, heart rate at
andomization, Killip class, and assigned treatment.emoglobin or hematocrit values are not obtained. This Tould lead to an underestimation of the number of TIMI
leeds. Third, our study was a post-hoc analysis of pooled
linical trial data that was collected prospectively. Therefore,
espite our robust statistical methods, there could be resid-
al confounding. Fourth, we reclassified bleeding events
rom the PARAGON B trial into the relevant GUSTO and
igure 2. (A) Hazard ratios of 30-day death or myocardial infarction (MI)
y Global Strategies for Opening Occluded Coronary Arteries (GUSTO)
nd Thrombolysis In Myocardial Infarction (TIMI) bleeding severity after
djustment for blood transfusion. Separate models constructed for each
cale. Adjusted for age, gender, weight, site, diabetes mellitus, smoking status,
rior angina, peripheral vascular disease, pre-randomization therapy, MI at
nrollment, systolic blood pressure at randomization, diastolic blood pressure
t randomization, heart rate at randomization, Killip class, assigned treatment,
nd blood transfusion. (B) Hazard ratios of six-month death or MI by
orsening GUSTO and TIMI bleeding severity after adjustment for blood
ransfusion. Separate models constructed for each scale. Adjusted for age,
ender, weight, site, diabetes mellitus, smoking status, prior angina, peripheral
ascular disease, pre-randomization therapy, MI at enrollment, systolic blood
ressure at randomization, diastolic blood pressure at randomization, heart rate
t randomization, Killip class, assigned treatment, and blood transfusion.IMI categories on the basis of the detailed clinical data that
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February 21, 2006:809–16 Bleeding by Two Different Scales and Outcomesas available. Nevertheless, because PARAGON B used a
efinition of bleeding that was slightly modified from either
he GUSTO or TIMI classification, this may limit our ability
o draw firm conclusions on the relationship between both
efinitions and clinical outcomes. Fifth, despite the strength of
he associations we found, we cannot definitively state causality
etween bleeding and death or MI due to the retrospective
ature of our study. Finally, our study population was
omprised of patients enrolled in clinical trials and may not
e fully representative of patients seen in clinical practice
25). Because the study population did not include higher-
isk patients, such as those who are older and have more
omorbidities, the risks may be underestimated.
onclusions. In conclusion, the results of our study indi-
ate that both the GUSTO and TIMI scales identify
atients with bleeding complications who are at risk for
hort- and intermediate-term death or MI. However, after
djusting for transfusion and when both scales were in-
luded in the same model, the increased risk with worsening
USTO bleeding persisted while the risk with TIMI
leeding did not. These results suggest that asymptomatic
ecreases in hemoglobin and/or hematocrit that do not
equire transfusion may not be associated with a worse
rognosis. Therefore, the issue of whether asymptomatic
ecreases in hemoglobin or hematocrit require aggressive
ransfusion deserves further scrutiny. This study also sug-
ests that a combination of the GUSTO scale and need for
ransfusion should be used to assess bleeding complications
n subsequent clinical trials of patients with ACS.
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